home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Software Vault: The Diamond Collection
/
The Diamond Collection (Software Vault)(Digital Impact).ISO
/
cdr16
/
med9505a.zip
/
M9550122.TXT
< prev
next >
Wrap
Text File
|
1995-03-04
|
2KB
|
40 lines
Document 0122
DOCN M9550122
TI Human pharmacokinetics and tolerability of L-697,639, a non-nucleoside
HIV-1 reverse transcriptase inhibitor.
DT 9505
AU Van Hecken A; Depre M; De Lepeleire I; Laskin O; Au T; Woolf E; Yeh KC;
De Schepper PJ; Department of Pharmacology, University of Leuven, School
of; Medicine, Belgium.
SO Int J Clin Pharmacol Res. 1994;14(2):45-50. Unique Identifier : AIDSLINE
MED/95137735
AB L-697,639, a potent and selective non-nucleoside inhibitor of HIV-1
reverse transcriptase and HIV-1 replication in vitro, was administered
to healthy male volunteers to investigate the pharmacokinetics and
tolerability of single and multiple oral doses. Single doses ranging
from 25 to 500 mg, and multiple doses of up to 100 mg every 12 h for ten
days, produced no clinically important adverse events. Dose
proportionality with respect to AUC was seen over the range of 25-100 mg
administered as a single dose. Single doses of 200 mg and 500 mg
resulted in an increase in AUC and Cmax that was less than proportional
to the increase in dose. The mean Cmax after single doses of 25 and 500
mg were 0.9 and 5.8 microM respectively. Mean Tmax values ranged from
1.7-3 h. Mean AUCs (0-48 h) were from 6.05 to 50.3 microM h after doses
from 25 to 500 mg respectively. After the 500-mg dose less than 0.7%
appeared unchanged in the urine over 48 hours. During multiple doses,
steady-state was reached on day 3 and slight accumulation occurred
(approximately 1.5-fold). L-697,639 was well tolerated for up to ten
days at doses that resulted in mean steady-state trough concentrations
that exceed their in-vitro susceptibilities.
DE Adult Benzoxazoles/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/
*PHARMACOKINETICS Chromatography, High Pressure Liquid Double-Blind
Method Human HIV-1/*ENZYMOLOGY Male Pyridones/ADMINISTRATION &
DOSAGE/ADVERSE EFFECTS/ *PHARMACOKINETICS Reverse
Transcriptase/*ANTAGONISTS & INHIB Spectrophotometry, Ultraviolet
Support, Non-U.S. Gov't CLINICAL TRIAL JOURNAL ARTICLE RANDOMIZED
CONTROLLED TRIAL
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).